OptimizeRx’s CEO Provides 2023 Midyear Strategic Update
- A leading suite of pharma tech solutions combined with deep brand penetration is driving revenue growth, resulting in improved profitability and KPIs through the remainder of 2023 and beyond
- With a comprehensive, digitally enabled enterprise point-of-care solution, the
OptimizeRxplatform now reaches 600 thousand health care professionals (HCPs) through point-of-care channels, 90% of all health system intranet/web portals, and over 2 million HCPs via social media
- 2023 guidance of at least a 10% increase in revenue is reaffirmed as midyear backlog visibility improves year-over-year to 60-70% of full year revenues
- Expected achievement of revenue between
$100- $120 millionwithin the next 18 to 24 months with 20% adjusted EBITDA margins
- Debt free balance sheet with approximately
$75 millionin cash $15 millionshare buyback program in place and active in recognition of undervalued share price
Dear OptimizeRx Shareholders,
Although we reported our financial earnings recently, I wanted to share in more detail what has me excited about our prospects. We re-founded the Company in 2016 with a driving, compulsive obsession — to empower life science organizations with the ability to nurture brand engagement with prescribers and patients alike. Our efforts to fulfill this mission have resulted in the buildout of a sophisticated, integrated suite of tech-enabled solutions operating at multiple touch points within the point of care. Our capabilities today are both far reaching and refined as compared to our early days as a start-up, with a single, standalone affordability messaging product.
Midyear revenue backlog
Today, our mission and passion continue to power drug maker brand awareness with prescribing physicians through patient treatment initiation, affordability and adherence. These efforts are packaged in a comprehensive, best-in-class enterprise solutions suite. Having finished the first quarter of 2023 achieving
Strategic roadmap and key growth pillars
Integrated engagement approach for all stakeholders
In spite of prolonged challenges with the macro-environment, coupled with the short-term noise of disengaged, standalone offerings from new competitors, we continue to future proof OptimizeRx’s utility to customers. Driving this dynamic is our machine learning based approach to integrated engagement at point-of-care and beyond.
Reaching deep across a comprehensive toolkit of solutions, we are delivering clinically relevant and contextual communications through electronic health records (EHRs). We further leverage patient journey milestones and physician engagement preferences to initiate timely follow-up communications.
Innovation and smart acquisitions currently driving growth
We spent two years developing our RWD.AI platform to extend engagement points with the same pool of prescribers outside the EHR and into care-adjacent digital settings such as social media where we have access to over 2 million HCP profiles and 90% of the nation’s health system intranet/websites. Since acquiring EvinceMed, that gave us a modular automation architecture, purpose-built for specialty therapies, we have continued to stay ahead of the industry curve with innovations that have enhanced our smart, data-driven technology offerings, which now includes web display. Now, our RWD.AI platform can eliminate bottlenecks, speed time to therapy, and reduce costs. We continue to build best-in-class reporting, a critical feature our customers tell us is necessary for all new business proposals as they look to gather information on audience, returns on investment (ROIs), and physician-level data. Through M&A and strategic partnerships, we are also actively seeking ways to further enhance revenue streams through omni-channel expansion, proprietary data analytics and insight generation.
18 to 24 months financial aspirations
As a result of our innovation and foresight, we firmly believe our solutions are meaningfully contributing to the improvement of patient care journeys and our customers’ marketing ROIs. We remain committed to our vision of profitable long-term growth, fully expecting to achieve 20% adjusted EBITDA - or better- on
We are evolving as a strategic partner by bringing broad reach and deep expertise in tech-enabled commercial solutions to life science customers’ communications between brands and patients.
Thank you once again for staying the course with us. We look forward to sharing our results on the next conference call.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans, and future performance. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended
Andy D’Silva, SVP Corporate Finance
Media Relations Contact
Investor Relations Contact
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d013edd9-218c-4e4e-8379-6220e0c78354
Source: OptimizeRx Corporation